Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Developing a hybrid nanoparticle-hydrogel platform for long non-coding RNA delivery in inflammatory bowel disease

EF 2021-22

Résumé
Globally, more than 6.8 million people are living with inflammatory bowel disease (IBD), a chronic inflammatory disease characterized by intestinal inflammation leading to bowel injury. Current therapies have improved quality of life and decreased risk of disease-related complications in patients with IBD. Forty percent of patients initially respond to treatments; however, these treatments become less effective over time. There is an urgent need for new and sustainable therapeutic treatments to address the clinical and economic burden caused by the disease. A solution is developing an orally administered drug delivery technology delivering long non-coding RNAs (lncRNAs) as an anti-inflammatory therapy for IBD.An ideal IBD treatment stops and reverses inflammation. LncRNAs are a class of nucleic acids involved in gene regulation. Several newly discovered lncRNAs can potentially stop inflammation, presenting an avenue by which we can utilize these molecules to modulate inflammation in IBD, provided these lncRNA can be delivered to the intestine. A new drug delivery vehicle composed of nanomaterials will be designed to protect these nucleic acids and carry it to the inflamed intestine to treat IBD.The drug delivery platform will be a novel lncRNA-based anti-inflammatory therapy for IBD. This technology aims to deliver large amounts of the lncRNA in the inflamed intestine to reduce the number of treatments. Patient compliance will be increased with the oral drug administration route. The capability to deliver multiple inflammation-reducing lncRNAs simultaneously creates a more comprehensive approach to treating this complex disease. With over 17,000 lncRNAs discovered to date, this class of nucleic acid holds tremendous potential in creating therapies beyond IBD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
466679
Name
Pang Janice
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing a hybrid nanoparticle-hydrogel platform for long non-coding RNA delivery in inflammatory bowel disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Delivery; Hydrogel; Inflammation; Inflammatory Bowel Disease; Long Non-Coding Rna; Nanotechnology; Rna Therapeutics
Abstract
Globally, more than 6.8 million people are living with inflammatory bowel disease (IBD), a chronic inflammatory disease characterized by intestinal inflammation leading to bowel injury. Current therapies have improved quality of life and decreased risk of disease-related complications in patients with IBD. Forty percent of patients initially respond to treatments; however, these treatments become less effective over time. There is an urgent need for new and sustainable therapeutic treatments to address the clinical and economic burden caused by the disease. A solution is developing an orally administered drug delivery technology delivering long non-coding RNAs (lncRNAs) as an anti-inflammatory therapy for IBD.An ideal IBD treatment stops and reverses inflammation. LncRNAs are a class of nucleic acids involved in gene regulation. Several newly discovered lncRNAs can potentially stop inflammation, presenting an avenue by which we can utilize these molecules to modulate inflammation in IBD, provided these lncRNA can be delivered to the intestine. A new drug delivery vehicle composed of nanomaterials will be designed to protect these nucleic acids and carry it to the inflamed intestine to treat IBD.The drug delivery platform will be a novel lncRNA-based anti-inflammatory therapy for IBD. This technology aims to deliver large amounts of the lncRNA in the inflamed intestine to reduce the number of treatments. Patient compliance will be increased with the oral drug administration route. The capability to deliver multiple inflammation-reducing lncRNAs simultaneously creates a more comprehensive approach to treating this complex disease. With over 17,000 lncRNAs discovered to date, this class of nucleic acid holds tremendous potential in creating therapies beyond IBD.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pang, Janice
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~